RxDoctor Payments Data

Kelley Scharrer

Nurse Practitioner · Columbia, TNNPI 1528250115

Payments from drug & device makers

$2,184in general payments, 2019–2025

Across 157 payments — averaging $13.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$522
  • Amgen$188
  • Lilly USA, LLC$112
  • Bayer$52
  • AstraZeneca$41
  • plus $124 from 6 others

What the payments were for

  • Food & beverage$2,184100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,184 in reported general payments places this provider in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,883
Medicare patients
21
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide52$76,125
OzempicSemaglutide33$33,812
Combivent RespimatIpratropium/Albuterol Sulfate12$5,495
Dexlansoprazole DrDexlansoprazole11$3,971
Albuterol Sulfate HfaAlbuterol Sulfate62$2,094
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,747
Pregabalin45$1,214
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$794
Atorvastatin Calcium59$712
Rosuvastatin Calcium45$698
Ondansetron OdtOndansetron26$687
Alprazolam70$669
Gabapentin54$669
Losartan Potassium48$658
Duloxetine Hcl25$642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$112$76,12552 claims
Novo NordiskOzempic$522$33,81233 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Columbia

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →